Nicholas Bevins, MD, PhD, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology Annual Meeting and Expo.
Kathleen Moore, MD, discusses the findings from the phase III FORWARD-1 trial that investigated mirvetuximab soravtansine in women with folate receptor alpha–positive platinum-resistant ovarian cancer. These findings were presented at the 2019 ESMO Congress.
Christopher J. Hoimes, DO, discusses an unmet medical need in the population of patients with urothelial carcinoma.
Pinkal Desai, MD, discusses the factors a practicing physician should consider when selecting an appropriate induction therapy for patients with acute myeloid leukemia.
William K. Oh, MD, discusses the rationale for presenting the data for the phase III ENZAMET trial in a plenary session at the 2019 ASCO Annual Meeting. He says these data were significant because it was a large randomized clinical trial for the treatment of newly diagnosed patients with metastatic hormone-sensitive prostate cancer.
Mark G. Kris, MD, discusses treatment options for <em>MET</em>-mutant non–small cell lung cancer.
Wasif M. Saif, MD, discusses available novel therapies for hepatocelluclar carcinoma.
Kevin Halling, MD, PhD, discussed the clinical utility of RNA-sequencing methods in patients with cancer at the 2019 Association for Molecular Pathology Annual Meeting and Expo. Halling says RNA sequencing is a very powerful diagnostic technique.
A. Oliver Sartor, MD, discusses a discrepancy found between conventional imaging and PSMA PET/CT scanning for prostate cancer.
Heinz-Josef Lenz, MD, FACP, discusses the advances in immunotherapy for treatment of metastatic colorectal cancer.
Shaji Kumar, MD, discusses the shift in the treatment landscape for patients with multiple myeloma, and how more patients are eligible for stem cell transplantation because of new criteria.
Leonard G. Gomella, MD, discusses the factors that determine which patients with prostate cancer should undergo genetic testing.
Basem William, MD, discusses challenges in treating patients with cutaneous and peripheral T-cell lymphomas, as well as the challenges in conducting clinical trials in this patient population.
David Maloney, MD, PhD, medical director, Cellular Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, discusses the results of the ZUMA trial and how chimeric antigen receptor CAR T-cell therapy is changing the treatment landscape for non-Hodgkin lymphoma.
Laura Quan Man Chow, MD, FRCPC, discusses the rationale for evaluating ceritinib in patients with <em>ALK</em>-positive non–small cell lung cancer in the ASCEND-7 trial.
Non-Hodgkin Lymphoma
Daniel Catenacci, MD, discusses how he makes decisions with immunotherapeutic agents for the treatment of patients with gastroesophageal junction cancer. He says he bases his sequencing decisions on a number of factors.
Hope S. Rugo, MD, discusses the potential role of immunotherapy for the treatment of patients with triple-negative breast cancer (TNBC), based on data from the KEYNOTE-522 clinical trial. Immunotherapy has been very exciting in this setting.
Winston Tan, MD, discusses the current treatment landscape for patients with thyroid cancer. He highlighted the importance of first determining if a patient with thyroid cancer has benign or malignant thyroid nodules, which can be identified with the use of diagnostic biopsies. He also discussed the standard-of-care treatment options for these different subtypes of patients once they are identified.
Simon Rule, MD, PhD, shares his thoughts on the FDA’s decision to grant zanubrutinib, a BTK inhibitor, priority review for the treatment of patients with mantle cell lymphoma. Should the drug be approved, it will be available for patients with MCL who have received at least 1 prior line of therapy.
Scott Kopetz, MD, PhD, explains how prognoses for patients with colorectal cancer differ based on whether their cancer is left-sided or right-sided and discusses how knowledge of these differences have led to the development of more agents to treat both groups of patients.
Lecia V. Sequist, MD, MPH, director, says that oncologists have developed a better understanding of what causes resistance to EGFR inhibitors in patients with non–small cell lung cancer through preclinical studies and biopsies. <em>MET</em> amplification was found to be one of the major causes of resistance to newer generation EGFR-targeted drugs.
John DiPersio, MD, PhD, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibody–drug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting.
